Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
RAHWAY, N.J.--(BUSINESS WIRE) July 27, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 27, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk(Stage IIB-IV) Melanoma
RAHWAY, N.J.& CAMBRIDGE, Mass.--(BUSINESS WIRE) July 26, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 26, 2023 Category: Pharmaceuticals Source Type: clinical trials
Concor ® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)
Condition: Healthy Interventions: Drug: First Test Concor (Fasted); Drug: First Reference Concor (Fasted); Drug: First Test Concor (Fed); Drug: First Reference Concor (Fed) Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
